Treatment with APS inhibited tumor development in MDSCs by reducing the proportion of Gr-1+CD11b+MDSCs and limiting vascular endothelial growth factor (VEGF) and IL-10 expression (Chai et al., 2012). The gene discussed is VEGFA; the disease is neoplasm.